SCHEMBL9924161

SCHEMBL9924161

O=C(/N=C(/Nc1cc(F)cc(Cl)c1)N[C@H]1CC[C@H](Nc2ncccn2)CC1)c1ccc(Cl)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 3/20 0.37
ADRA2A P08913 2/20 0.37
HRH1 P35367 2/20 0.37
HTR2B P41595 2/20 0.37
ADRA1A P35348 1/20 0.37
PDE4B Q07343 2/20 0.37
PDE4A P27815 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
EPHX2 P34913 2/20 0.36
GRM4 Q14833 1/20 0.36
SLC6A9 P48067 4/20 0.36
SLC6A5 Q9Y345 1/20 0.36
TP53 P04637 1/20 0.36
MDM2 Q00987 1/20 0.36
MC5R P33032 1/20 0.35
CYP2D6 P10635 1/20 0.35
KCNQ3 O43525 1/20 0.34
KCNQ2 O43526 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17206691 0.93 KCNQ3 (0.41) MCHR1ADRA2AHRH1HTR2BADRA1A
SCHEMBL9924419 0.93 KCNQ3 (0.41) MCHR1ADRA2AHRH1HTR2BADRA1A
SCHEMBL9901952 0.93 KCNQ3 (0.41) MCHR1ADRA2AHRH1HTR2BADRA1A
SCHEMBL9900852 0.93 KCNQ3 (0.41) MCHR1ADRA2AHRH1HTR2BADRA1A
SCHEMBL9900854 0.93 KCNQ3 (0.41) MCHR1ADRA2AHRH1HTR2BADRA1A
SCHEMBL17206704 0.92 CYP2D6 (0.37) PDE4BPDE4APDE4CPDE4DEPHX2
SCHEMBL9924215 0.85 SLC6A9 (0.41) EPHX2GRM4SLC6A9SLC6A5TP53
SCHEMBL9924439 0.84 GRM5 (0.39) GRM4SLC6A9TP53KCNQ3KCNQ2
SCHEMBL9924083 0.84 NPC1 (0.44) MCHR1HTR2BGRM4TP53MDM2
SCHEMBL17206719 0.83 DCUN1D1 (0.47) EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9169199-B2 Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2015-10-27 US disclosed
WO-2012078867-A2 CYCLOALKYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF LYCERA CORPORATION (US) 2012-06-14 WO disclosed